--- title: "Huatai Securities: Gilead's acquisition of Ouro reflects the value of the KEYMED platform" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/280560144.md" description: "The Huatai Securities report points out that the acquisition deal between KEYMED BIO-B and Gilead reflects its platform value. Gilead will make an upfront payment of $1.675 billion and a $500 million milestone acquisition of Ouro, while KEYMED will receive $250 million as an upfront payment and $70 million in milestones, and will continue to enjoy sales sharing rights for CM336. The firm believes this transaction will accelerate the global value realization of CM336 and reiterates its optimism regarding KEYMED's related assets, maintaining a \"Buy\" rating with a target price of 91.08 yuan" datetime: "2026-03-26T03:21:02.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/280560144.md) - [en](https://longbridge.com/en/news/280560144.md) - [zh-HK](https://longbridge.com/zh-HK/news/280560144.md) --- > 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/280560144.md) | [English](https://longbridge.com/en/news/280560144.md) # Huatai Securities: Gilead's acquisition of Ouro reflects the value of the KEYMED platform Huatai Securities published a report stating that KEYMED BIO-B (02162.HK) announced that Gilead will make an initial payment of USD 1.675 billion and a milestone payment of USD 500 million to acquire Ouro, which is the NewCo carrying the overseas rights for CM336. Upon completion of the transaction, KEYMED will receive USD 250 million as an initial payment and USD 70 million as a milestone based on its equity in Ouro, while continuing to enjoy sales revenue sharing rights for CM336. The firm believes that this acquisition is an important milestone for KEYMED's TCE platform value recognized by MNC, which will significantly accelerate the global value realization of CM336: (1) Gilead has a strong global clinical and commercialization network, and in recent years has continued to increase its investment in the BCMA target and autoimmune fields, with CM336 having synergistic potential with its existing pipeline; (2) CM336 has outstanding efficacy and safety data, and its global progress in autoimmune indications is in the leading tier; (3) The transaction will directly bring cash flow back to KEYMED, strongly supporting the research and commercialization of other core pipelines. The firm reiterates its positive outlook on the continued valuation realization of assets such as Siponimod, CMG901, and CM512. It maintains a "Buy" rating with a target price of 91.08 yuan ### 相關股票 - [iShares Global Healthcare (IXJ.US)](https://longbridge.com/zh-HK/quote/IXJ.US.md) - [Minsheng Royal CSI Biotechnology Theme ETF (516930.CN)](https://longbridge.com/zh-HK/quote/516930.CN.md) - [Bosera Hang Seng Health Care ETF(QDII) (513060.CN)](https://longbridge.com/zh-HK/quote/513060.CN.md) - [iShares US Pharma (IHE.US)](https://longbridge.com/zh-HK/quote/IHE.US.md) - [Direxion S&P Biotech Bull 3X (LABU.US)](https://longbridge.com/zh-HK/quote/LABU.US.md) - [Gilead Sciences (GILD.US)](https://longbridge.com/zh-HK/quote/GILD.US.md) - [E Fund CSI Biotechnology Theme ETF (159837.CN)](https://longbridge.com/zh-HK/quote/159837.CN.md) - [Bosera Hang Seng SCHK Innovative Drug Select ETF (520690.CN)](https://longbridge.com/zh-HK/quote/520690.CN.md) - [Founder Fubon CSI Medicine and Medical Device Innovation ETF (560600.CN)](https://longbridge.com/zh-HK/quote/560600.CN.md) - [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-HK/quote/FBT.US.md) - [Penghua SSE STAR Biology and Medicine ETF (588250.CN)](https://longbridge.com/zh-HK/quote/588250.CN.md) - [Yinhua CSI Innovative Drugs Industry ETF (159992.CN)](https://longbridge.com/zh-HK/quote/159992.CN.md) - [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-HK/quote/XBI.US.md) - [ChinaAMC CSI Biotechnology Theme ETF (516500.CN)](https://longbridge.com/zh-HK/quote/516500.CN.md) - [Guotai CSI Bio-medicine ETF (512290.CN)](https://longbridge.com/zh-HK/quote/512290.CN.md) - [Tianhong CNI BIOMEDICINE ETF (159859.CN)](https://longbridge.com/zh-HK/quote/159859.CN.md) - [Huaan Hang Seng Biotech ETF (159102.CN)](https://longbridge.com/zh-HK/quote/159102.CN.md) - [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-HK/quote/IBB.US.md) - [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-HK/quote/PBE.US.md) - [Gilead Sciences, Inc. (GIS.DE)](https://longbridge.com/zh-HK/quote/GIS.DE.md) - [ICBCCS SSE STAR Biology and Medicine ETF (588860.CN)](https://longbridge.com/zh-HK/quote/588860.CN.md) - [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-HK/quote/SBIO.US.md) - [ChinaAMC Hang Seng Biotechnology Technology ETF(QDII) (159892.CN)](https://longbridge.com/zh-HK/quote/159892.CN.md) - [China Southern Hang Seng Biotech ETF(QDII) (159615.CN)](https://longbridge.com/zh-HK/quote/159615.CN.md) - [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-HK/quote/BBH.US.md) - [GF CSI HK Innovative Drugs Industry ETF(QDII) (513120.CN)](https://longbridge.com/zh-HK/quote/513120.CN.md) - [Ping An CSI Medicine and Medical Device Innovation ETF (516820.CN)](https://longbridge.com/zh-HK/quote/516820.CN.md) - [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-HK/quote/BIB.US.md) - [ChinaAMC SSE STAR Biology and Medicine ETF (588130.CN)](https://longbridge.com/zh-HK/quote/588130.CN.md) - [Hwabao WP Hang Seng SCHK Innovative Drug Select ETF (520880.CN)](https://longbridge.com/zh-HK/quote/520880.CN.md) - [E Fund CSI 300 Health Care ETF (512010.CN)](https://longbridge.com/zh-HK/quote/512010.CN.md) - [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/zh-HK/quote/IBBQ.US.md) - [KEYMED BIO-B (02162.HK)](https://longbridge.com/zh-HK/quote/02162.HK.md) - [China Merchants CSI Biotechnology Theme ETF (159849.CN)](https://longbridge.com/zh-HK/quote/159849.CN.md) - [ChinaAMC SSE Health Care ETF Initiating Fund (510660.CN)](https://longbridge.com/zh-HK/quote/510660.CN.md) - [Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF (159506.CN)](https://longbridge.com/zh-HK/quote/159506.CN.md) - [E Fund Hang Seng SCHK Innovative Drug ETF (159316.CN)](https://longbridge.com/zh-HK/quote/159316.CN.md) - [Penghua CSI HK Connect Health Care Composite ETF (513700.CN)](https://longbridge.com/zh-HK/quote/513700.CN.md) - [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-HK/quote/ARKG.US.md) - [VG Health (VHT.US)](https://longbridge.com/zh-HK/quote/VHT.US.md) - [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-HK/quote/XLV.US.md) ## 相關資訊與研究 - [Gilead extends Arcellx tender offer expiration date](https://longbridge.com/zh-HK/news/281422486.md) - [Galapagos, Gilead Enter Binding Agreement On Ouro Medicines Acquisition](https://longbridge.com/zh-HK/news/281128280.md) - [Annovis Bio Director Purchased Shares Worth Over $1.4M](https://longbridge.com/zh-HK/news/281662341.md) - [Assessing BioArctic (OM:BIOA B) Valuation After New Lecanemab Data And Regulatory Milestones](https://longbridge.com/zh-HK/news/281644038.md) - [BMS, Novartis, Gilead, Iovance dinged in CBER untitled letters](https://longbridge.com/zh-HK/news/281059389.md)